Study guide
8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control
Key Takeaways Explain This Topic AI
The Canadian Cardiovascular Society (CCS) algorithm (CCS-CHADS-65) mandates oral anticoagulation (DOAC preferred over warfarin) for any patient with non-valvular AF who is Age >= 65, has a prior stroke/TIA, or possesses >= 1 CHADS risk factor (Congestive heart failure, Hypertension, Diabetes).
Antiplatelet therapy (acetylsalicylic acid) is NOT recommended for stroke prevention in atrial fibrillation; patients under 65 without prior stroke/TIA, CHF, HTN, or diabetes require no antithrombotic therapy unless arterial vascular disease is present.
Clinical trials (AFFIRM, RACE) establish that rate control is non-inferior to rhythm control for survival and thromboembolic prevention; rhythm control is reserved for persistent symptoms despite rate control, heart failure caused by AF, or newly diagnosed patients seeking early rhythm preservation.
When using Class Ic antiarrhythmics (flecainide, propafenone) for 'pill-in-the-pocket' conversion of lone AF, an AV nodal blocking agent (beta-blocker or non-DHP CCB) MUST be co-administered >= 30 minutes prior to prevent 1:1 AV conduction during atrial flutter.
Restoring sinus rhythm when AF duration exceeds 48 hours (or is unknown) requires therapeutic anticoagulation for at least 3 weeks before and 4 weeks after cardioversion, or a transesophageal echocardiogram (TEE) ruling out left atrial appendage thrombus followed by 4 weeks of anticoagulation.
Last updated: October 2026
8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in Canadian clinical practice, affecting approximately 1% to 2% of the population and > 10% of individuals aged 80 and older. It is characterized by chaotic, disorganized atrial electrical activation (350 to 600 depolarizations/min) that leads to an irregular, typically rapid ventricular response.
Management of AF rests on three interconnected clinical pillars: (1) Stroke prevention through evidence-based anticoagulation, (2) Ventricular rate control to preserve hemodynamics and prevent tachycardia-induced cardiomyopathy, and (3) Rhythm control (antiarrhythmic drugs, cardioversion, catheter ablation) in selected symptomatic patients.
Pathophysiology and Clinical Consequences of Atrial Fibrillation
Loss of Atrial Systole ('Atrial Kick') : In a healthy heart, active atrial contraction contributes 20% to 30% of left ventricular end-diastolic filling. Loss of this synchronized kick in AF precipitates an immediate decline in cardiac output, frequently triggering acute pulmonary congestion or fatigue in patients with baseline diastolic dysfunction or heart failure.
Rapid Ventricular Response (RVR) : Ventricular rates often range between 110 and 180 bpm at rest. Prolonged uncontrolled tachycardia impairs myocardial perfusion, increases oxygen demand, and causes tachycardia-induced cardiomyopathy —a reversible form of systolic heart failure.
Thromboembolic Stroke : Ineffective, fibrillating atria create regional blood stasis, predominantly within the trabeculated left atrial appendage (LAA) . Thrombi formed in the LAA can embolize through the carotid circulation, resulting in severe ischemic stroke. AF-related strokes are notoriously larger, more disabling, and associated with double the mortality of non-AF strokes.
Stroke Prevention: The CCS-CHADS-65 Algorithm
Unlike American and European guidelines that rely on the complex CHA2DS2-VASc score, the Canadian Cardiovascular Society (CCS) developed the streamlined CCS-CHADS-65 algorithm . This algorithm recognizes that age >= 65 is the single most powerful continuous risk factor for stroke , rendering additional risk scoring above age 65 redundant. CCS-CHADS-65 DECISION ALGORITHM
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Patient with Documented Atrial Fibrillation or Atrial Flutter │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- ▼
Mechanical Heart Valve or Moderate-to-Severe Mitral Stenosis?
- ┌───────────────────┴───────────────────┐
- YES NO
- │ ▼
▼ Age >= 65 OR Prior Stroke / TIA?
- WARFARIN MANDATORY (Target 2.5-3.5) │
- (DOACs are CONTRAINDICATED) ┌─────────────┴─────────────┐
- YES NO
- │ ▼
│ Presence of CHADS Risk Factors?
- │ - Congestive Heart Failure
- │ - Hypertension
- │ - Diabetes Mellitus
- │ │
- │ ┌───────────┴───────────┐
- │ YES NO
- │ │ ▼
- ▼ ▼ Arterial Vascular Disease?*
- ORAL ANTICOAGULATION │
- (DOAC Preferred over Warfarin) ┌───────┴───────┐
- YES NO
- │ ▼
- ▼ NO ANTITHROMBOTIC
- ASA 81 mg THERAPY
- daily
*Arterial vascular disease includes prior myocardial infarction, peripheral arterial disease, or complex aortic plaque.
Detailed Steps of the CCS Algorithm:
Valvular AF Screen : If the patient has a mechanical prosthetic heart valve or moderate-to-severe rheumatic mitral stenosis , the patient has 'valvular AF' and requires Warfarin (INR target 2.5 to 3.5 for mechanical mitral, 2.0 to 3.0 for mechanical aortic). DOACs are strictly contraindicated in mechanical heart valves (RE-ALIGN trial).
Age & Stroke History : If non-valvular, does the patient meet Age >= 65 OR have a history of prior Stroke, TIA, or systemic embolism ? If YES --> Oral Anticoagulation (OAC) is recommended regardless of other factors.
CHADS Risk Factors : If Age < 65 without prior stroke/TIA, evaluate the remaining CHADS risk factors:
- C : Congestive Heart Failure (recent decompensation, HFrEF, or HFpEF)
- H : Hypertension (treated or untreated blood pressure > 140/90 mmHg)
- D : Diabetes mellitus (type 1 or type 2)
If the patient has >= 1 of these risk factors --> Oral Anticoagulation (OAC) is recommended.
No CHADS Risk Factors : If Age < 65 and none of the CHADS risk factors are present:
Check for Arterial Vascular Disease (coronary artery disease, prior MI, coronary stent, peripheral arterial disease):
If vascular disease is present --> ASA 81 mg once daily .
If NO vascular disease is present --> No antithrombotic therapy .
Important
CCS Policy on Antiplatelet Monotherapy :
Acetylsalicylic acid (ASA) is no longer recommended for stroke prevention in atrial fibrillation . Multiple large trials demonstrated that ASA provides negligible protection against cardioembolic stroke while significantly increasing major gastrointestinal bleeding. In patients requiring stroke prevention, oral anticoagulants (DOACs or warfarin) are mandatory. In young patients without stroke risk factors or vascular disease, no antithrombotic therapy should be prescribed.
Rate Control vs. Rhythm Control Strategy
The fundamental clinical decision in managing AF symptoms is whether to pursue rate control or rhythm control:
Landmark Clinical Evidence : The landmark AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) and RACE trials demonstrated that a routine rhythm-control strategy using antiarrhythmic drugs does not improve survival or reduce stroke risk compared to a rate-control strategy. Antiarrhythmic medications were associated with more adverse drug reactions, proarrhythmic events, and hospitalizations.
Rate Control as Default : Rate control is the preferred initial strategy for the majority of elderly, sedentary, or minimally symptomatic patients.
Indications for Rhythm Control :
Persistent, debilitating symptoms (fatigue, palpitations, dyspnea) despite adequate rate control.
Inability to achieve target ventricular rate control with safe doses of AV nodal blockers.
Heart failure clearly precipitated or worsened by AF (tachycardia-induced cardiomyopathy).
Younger patients wishing to avoid lifelong rate-controlling medications.
Newly diagnosed AF within 1 year, where early rhythm control (antiarrhythmics or catheter ablation) has been shown to reduce cardiovascular death and stroke ( EAST-AFNET 4 trial ).
Note
Anticoagulation Is Independent of Rhythm Strategy : Successful restoration and maintenance of sinus rhythm does not eliminate stroke risk. Asymptomatic, silent recurrences of AF are extremely common. Anticoagulation decisions must be guided strictly by the patient's CCS-CHADS-65 score , not by whether they are currently in sinus rhythm!
Ventricular Rate Control Pharmacotherapy
Rate control slows conduction velocity and prolongs the refractory period of the atrioventricular (AV) node, protecting the ventricles from rapid atrial impulses.
Target Heart Rate: Lenient vs. Strict Control
Lenient Rate Control : Resting heart rate < 110 bpm . In the RACE II trial , lenient rate control was proven to be non-inferior to strict control regarding cardiovascular mortality, heart failure hospitalizations, and stroke, with significantly fewer clinic visits and drug dose titrations.
Strict Rate Control : Resting heart rate < 80 bpm and exercise heart rate < 110 bpm . Indicated if the patient remains symptomatic under lenient control, or in patients with HFrEF or suspected tachycardiomyopathy.
Rate Control Agents: Clinical Comparison
Drug Class Specific Agents Mechanism & Clinical Role Important Contraindications & Monitoring
Beta-Blockers Metoprolol , Bisoprolol , Atenolol , Carvedilol First-line agents for rate control. Highly effective at rest and during exertion (blunts exercise-induced sympathetic surge). Preferred in CAD, post-MI, and HFrEF Avoid in severe bronchospastic asthma and second- or third-degree AV block without pacemaker. In HFrEF, use only evidence-based beta-blockers (bisoprolol, carvedilol, metoprolol succinate)
Non-DHP Calcium Channel Blockers Diltiazem , Verapamil First-line agents in patients with preserved LVEF (> 40%). Excellent rate control at rest and during exercise. Preferred in COPD/asthma where beta-blockers are avoided Strictly contraindicated in HFrEF (LVEF <= 40%) due to negative inotropy. Strong CYP3A4 inhibitors (interact with statins, DOACs, cyclosporine)
Cardiac Glycoside Digoxin Enhances vagal parasympathetic tone at the AV node. Effective for rate control at rest only ; ineffective during exertion or emotional stress. Useful add-on in sedentary elderly or HFrEF Narrow therapeutic window (0.5 to 0.9 ng/mL). Toxicity exacerbated by hypokalemia and hypomagnesemia. Cleared renally; reduce dose in renal dysfunction
Class III Antiarrhythmic Amiodarone (IV/Oral) Exhibits non-competitive alpha- and beta-blocking and calcium channel-blocking properties. Reserved for acute rate control in critically ill patients with refractory tachycardia or severe HFrEF Not recommended for long-term routine rate control due to extensive organ toxicities
Rhythm Control Pharmacotherapy: Antiarrhythmic Drugs (AADs)
Antiarrhythmic drugs are classified using the Vaughan Williams classification system . In atrial fibrillation, rhythm control relies primarily on Class Ic and Class III agents.
1. Class Ic Agents: Flecainide & Propafenone
Mechanism : Potent sodium channel blockers that significantly slow phase 0 cardiac depolarization and conduction velocity without altering action potential duration.
Clinical Indications : Maintenance of sinus rhythm or chemical cardioversion in patients with structurally normal hearts (absence of ischemic heart disease, prior MI, left ventricular hypertrophy, or heart failure).
The 'Pill-in-the-Pocket' Strategy : In selected outpatients with infrequent, symptomatic episodes of paroxysmal AF, a self-administered single oral dose of flecainide (200 to 300 mg) or propafenone (450 to 600 mg) can terminate the arrhythmia at home, avoiding emergency department visits.
Caution
The Mandatory AV Nodal Blocker Rule with Class Ic Agents :
Class Ic agents slow the electrical rate of atrial fibrillation, which can inadvertently convert the irregular rhythm into organized atrial flutter with an atrial rate of ~200 bpm. If the AV node can conduct at this lower frequency, the normal physiological 2:1 or 3:1 AV block can suddenly convert into a catastrophic 1:1 AV conduction , driving the ventricles at an extremely rapid rate of 200 bpm with severe hemodynamic collapse. To prevent this, clinicians MUST always co-prescribe an AV nodal blocking agent (a beta-blocker or non-DHP CCB) administered at least 30 minutes prior to or concomitantly with the Class Ic agent!
2. Class III Agents: Amiodarone, Sotalol & Dronedarone
Class III antiarrhythmics block cardiac potassium repolarizing channels, prolonging the action potential duration and effective refractory period.
A. Amiodarone (Cordarone)
Efficacy : The most effective antiarrhythmic drug for maintaining sinus rhythm and the only agent proven safe in patients with severe structural heart disease, severe left ventricular hypertrophy, and HFrEF.
Pharmacokinetics : Extremely lipophilic with a massive apparent volume of distribution (Vd > 60 L/kg) and a prolonged elimination half-life of 40 to 60 days . Contains two iodine atoms, representing 37% iodine by molecular weight.
Organ Toxicities & Monitoring Protocol :
Pulmonary Toxicity : Pulmonary fibrosis or hypersensitivity pneumonitis occurs in up to 5% of patients and can be fatal. Baseline and annual chest X-ray; pulmonary function tests (DLCO) if dyspnea or cough occurs.
Thyroid Dysfunction : Baseline and every 6-month thyroid stimulating hormone (TSH) and free T4. Causes hypothyroidism (blocks peripheral conversion of T4 to T3) or hyperthyroidism (iodine-induced Jod-Basedow effect or destructive thyroiditis).
Ocular Deposits : Corneal microdeposits occur in > 90% of patients (harmless, causes halos around lights). However, optic neuropathy or optic neuritis causes progressive visual loss and requires immediate drug cessation.
Hepatotoxicity : Serum aminotransferases (AST/ALT) rise in 15% to 30%. Check baseline and every 6-month LFTs; discontinue if transaminases exceed 3 times upper limit of normal.
Dermatologic : Photosensitivity (counsel on sunscreen and sun avoidance); prolonged use causes irreversible slate-gray or blue skin pigmentation.
Cardiac : Severe bradycardia, AV block, and QT prolongation. Note: Despite marked QTc prolongation, amiodarone causes uniform prolongation of myocardial repolarization and carries a very low incidence (< 1%) of Torsades de Pointes.
Drug-Drug Interactions : Potent inhibitor of CYP3A4, CYP2C9, CYP2D6, and P-glycoprotein. Empirically reduce the maintenance dose of Digoxin by 50% and Warfarin by 30% to 50% when initiating amiodarone.
B. Sotalol (Sotacor)
Combines non-selective beta-blockade with Class III potassium channel blockade.
High Risk of Torsades de Pointes : Significantly prolongs QT interval; risk of proarrhythmia increases with higher doses, hypokalemia, hypomagnesemia, female sex, and renal impairment.
Safety Mandate : Contraindicated if baseline QTc > 450 ms or creatinine clearance < 30 mL/min. Inpatient continuous ECG telemetry monitoring for at least 3 days (5 to 6 doses) is standard during therapy initiation.
C. Dronedarone (Multaq)
Non-iodinated amiodarone derivative designed to minimize pulmonary and thyroid toxicity.
Critical Contraindications : Contraindicated in patients with permanent AF (PALLAS trial) and in patients with NYHA Class III to IV or recently decompensated HFrEF (ANDROMEDA trial), where it significantly increased cardiovascular death.
Cardioversion Rules and Anticoagulation Mandates
Restoration of sinus rhythm via synchronized direct-current electrical cardioversion (DCCV) or chemical cardioversion carries an inherent risk of dislodging a pre-existing atrial thrombus: CARDIOVERSION ANTICOAGULATION PROTOCOL
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Patient with AF Scheduled for Cardioversion (Electrical or Chemical) │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- ▼
AF Duration >= 48 Hours?
- ┌───────────────────┴───────────────────┐
- YES (or Unknown Duration) NO (< 48 Hours)
- │ │
- ┌───────────┴───────────┐ ▼
- ▼ ▼ Cardiovert Promptly;
- OPTION 1: OPTION 2: Administer Anticoagulant
- Therapeutic OAC TEE Guided: at presentation;
- for >= 3 WEEKS Perform TEE; Continue Anticoagulation
- PRIOR to If NO LAA thrombus, for >= 4 WEEKS
- Cardioversion Cardiovert with post-cardioversion
- │ Heparin/DOAC │
- └───────────┬───────────┘ │
- ▼ ▼
- Cardioversion Performed Cardioversion Performed
- │ │
- ▼ ▼
- CONTINUE THERAPEUTIC ANTICOAGULATION CONTINUE THERAPEUTIC ANTICOAGULATION
- FOR AT LEAST 4 WEEKS POST-PROCEDURE FOR AT LEAST 4 WEEKS POST-PROCEDURE
- (Atrial stunning persists for weeks) (Lifelong if CCS-CHADS-65 >= 1)
Note
CCS nuance for AF under 48 hours: the CCS AF guideline allows early cardioversion without 3 weeks of prior anticoagulation only when AF has lasted less than 12 hours with no recent stroke or TIA, or 12 to 48 hours with a CHADS2 score of 0 or 1. Patients with AF of 12 to 48 hours and a CHADS2 score of 2 or more, or a recent stroke or TIA, should receive 3 weeks of anticoagulation or a TEE-guided approach first. Long-term anticoagulation after cardioversion follows the CCS algorithm, not the cardioversion itself.
AF Duration >= 48 Hours (or Unknown Duration) :
Option 1 (Standard) : Therapeutic oral anticoagulation (DOAC or warfarin with INR 2.0 to 3.0) for a minimum of 3 consecutive weeks prior to cardioversion , followed by therapeutic anticoagulation for at least 4 weeks post-cardioversion .
Option 2 (TEE-Guided) : Perform a transesophageal echocardiogram (TEE) to directly visualize the left atrial appendage. If no thrombus is detected, cardioversion may be performed immediately after administering therapeutic anticoagulation (e.g., LMWH, IV heparin, or a DOAC dose). Therapeutic anticoagulation must still be continued for at least 4 weeks post-cardioversion .
Why 4 Weeks Post-Cardioversion? : Even after sinus rhythm is successfully restored, the mechanical pumping function of the atria remains impaired for days to weeks—a phenomenon known as atrial stunning . Thrombi can form in stunned atria even in sinus rhythm; therefore, 4 weeks of post-procedure anticoagulation is non-negotiable.
Long-Term Anticoagulation : After the 4-week post-cardioversion window, the decision to continue lifelong anticoagulation is based solely on the patient's underlying CCS-CHADS-65 stroke risk profile , NOT on maintenance of sinus rhythm.
Hemodynamically Unstable AF : In patients presenting with acute pulmonary edema, cardiogenic shock, or severe myocardial ischemia, immediate synchronized electrical cardioversion is mandatory. Therapeutic anticoagulation (IV heparin bolus or LMWH) should be administered immediately prior to shock, followed by 4 weeks of post-cardioversion anticoagulation.